Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Oncology›Clinical Question·Updated Jul 3, 2026·v1

Role of immunotherapy in early-stage non-small cell lung cancer (NSCLC)

Evidence-based overview of Role of immunotherapy in early-stage non-small cell lung cancer (NSCLC).

Moderate Evidence32 references·726 words·3 min read·v1
Oncologyrole of immunotherapy in early-stage non-small cell lung cancer (nsclc)
Immunotherapy has revolutionized the management of resectable stage II-III non-small cell lung cancer (NSCLC). Integrating immune checkpoint inhibitors (ICIs) into neoadjuvant or perioperative regimens significantly improves pathologic response and survival. This bedside reference summarizes pivotal trial data, surgical considerations, and biomarker-driven patient selection for optimal clinical outcomes.

Deep Dive — Evidence Details

References

  1. [1]

    Kidane B, Bott M, Spicer J et al.. “The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer.” The Journal of thoracic and cardiovascular surgery (2023). PMID: 37306641 ↗

    L5GUIDELINECited in: Bottom Line, Current Evidence and Standard, On the Horizon
  2. [2]

    Scherpereel A, Martin E, Brouchet L et al.. “Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancer.” Lung cancer (Amsterdam, Netherlands) (2023). PMID: 36682142 ↗

    L5GUIDELINECited in: Bottom Line, Current Evidence and Standard, On the Horizon
  3. [3]

    . “[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)].” Zhonghua zhong liu za zhi [Chinese journal of oncology] (2025). PMID: 40796288 ↗

    L5GUIDELINECited in: Bottom Line, Current Evidence and Standard
  4. [4]

    Bertoglio P, Gallina FT, Balzani E et al.. “Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysis.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42000405 ↗

    L1SR_OBSCited in: Bottom Line, Current Evidence and Standard
  5. [5]

    Barbosa S, de Siqueira Silva A, Rodrigues LB. “Robotic-assisted versus video-assisted thoracoscopic surgery for non-small cell lung cancer after neoadjuvant immunotherapy: a systematic review and meta-analysis.” Journal of robotic surgery (2026). PMID: 41931195 ↗

    L1SR_OBSCited in: Bottom Line, Current Evidence and Standard
  6. [6]

    Liu W, Feng Z, Zhang M et al.. “Predicting neoadjuvant immunotherapy efficacy with machine learning models in non-small cell lung cancer: A systematic review and meta analysis.” International journal of medical informatics (2026). PMID: 41719848 ↗

    L1SR_OBSCited in: Bottom Line, Current Evidence and Standard
  7. [7]

    Spicer JD, Cascone T, Wynes MW et al.. “Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2024). PMID: 38901648 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard, On the Horizon
  8. [8]

    Kim SS, Cooke DT, Kidane B et al.. “The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-small Cell Lung Cancer.” The Annals of thoracic surgery (2024). PMID: 39424119 ↗

    L5REVIEW_NARRATIVECited in: Bottom Line, Current Evidence and Standard, On the Horizon
  9. [9]

    Mitome N, Hamada A, Wakabayashi M et al.. “A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI).” Clinical lung cancer (2026). PMID: 42107198 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
  10. [10]

    Provencio M, Awad MM, Spicer JD et al.. “Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.” Nature cancer (2026). PMID: 41507539 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  11. [11]

    Tanaka F, Watanabe Y, Sugawara S et al.. “Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T.” Cancer science (2025). PMID: 41431434 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  12. [12]

    Cuppens K, Wiesweg M, Baas P et al.. “Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung).” European journal of cancer (Oxford, England : 1990) (2025). PMID: 41389771 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  13. [13]

    Wang C, Wang W, Liu H et al.. “Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41344593 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
  14. [14]

    Martin LW, Wang X, Kozono D et al.. “CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46).” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 41880691 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard
  15. [15]

    Yan Y, Han Y, Niu Z et al.. “Conversion Surgery After Induction Therapy for Initially Unresectable Stage III Non-small Cell Lung Cancer: A Proof-of-Concept Trial.” Annals of surgical oncology (2026). PMID: 41880079 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard
  16. [16]

    Zhai W, Liang D, Yu X et al.. “Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 41980306 ↗

    L3COHORTCited in: Current Evidence and Standard
  17. [17]

    Pan Y, Sun C, Xu H et al.. “Pathologic response and nodal status guide adjuvant immunotherapy in non-small cell lung cancer after neoadjuvant chemoimmunotherapy: An eastern Asian cohort study.” The Journal of thoracic and cardiovascular surgery (2026). PMID: 41765326 ↗

    L3COHORTCited in: Current Evidence and Standard
  18. [18]

    Zhang W, Dai T, Wang D et al.. “Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials.” BMC cancer (2024). PMID: 39696048 ↗

    L1SR_MA_RCTCited in: Applicability and Caveats, On the Horizon
  19. [19]

    de Moraes FCA, Pasqualotto E, de Oliveira Rodrigues ALS et al.. “Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized controlled trials.” European journal of clinical pharmacology (2024). PMID: 39542906 ↗

    L1SR_MA_RCTCited in: Applicability and Caveats
  20. [20]

    Teodonio L, Peritore V, Andreetti C. “Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review.” Updates in surgery (2025). PMID: 40996635 ↗

    L2SR_OBSCited in: Applicability and Caveats
  21. [21]

    Zhang Z, Lin Y, Chen S. “Efficacy of neoadjuvant, adjuvant, and perioperative immunotherapy in non-small cell lung cancer across different PD-L1 expression levels: a systematic review and meta-analysis.” Frontiers in immunology (2025). PMID: 40463367 ↗

    L1SR_OBSCited in: Applicability and Caveats
  22. [22]

    Yang X, Xing Z, Long S et al.. “Comparative effectiveness for early-stage NSCLC without lymph node involvement based on prospective studies.” International journal of surgery (London, England) (2025). PMID: 40434735 ↗

    L1SR_OBSCited in: Applicability and Caveats
  23. [23]

    Liu Y, Long J, Deng H et al.. “Neoadjuvant immunotherapy for NSCLC: superior combination strategies, optimal treatment cycles, and predictive indicators from a Bayesian meta-analysis.” Frontiers in immunology (2025). PMID: 40213564 ↗

    L1SR_OBSCited in: Applicability and Caveats
  24. [24]

    Nuccio A, Salomone F, Servetto A et al.. “Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis.” Journal of the National Cancer Institute (2025). PMID: 40210599 ↗

    L1SR_OBSCited in: Applicability and Caveats
  25. [25]

    . “[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].” Zhonghua zhong liu za zhi [Chinese journal of oncology] (2023). PMID: 37460438 ↗

    L5GUIDELINECited in: On the Horizon
  26. [26]

    Chen K, Wang X, Yue R et al.. “Efficacy and safety of immune checkpoint inhibitors as neoadjuvant therapy in perioperative patients with non-small cell lung cancer: a network meta-analysis and systematic review based on randomized controlled trials.” Frontiers in immunology (2024). PMID: 39416776 ↗

    L1SR_MA_RCTCited in: On the Horizon
  27. [27]

    Patel AJ, Hemead H, Law J et al.. “Impact of the timing of immunotherapy administration on overall survival for resectable non-small cell lung cancer (iACORN study): A systematic review and meta-analysis of randomised trials.” European journal of cancer (Oxford, England : 1990) (2024). PMID: 39551030 ↗

    L1SR_OBSCited in: On the Horizon
  28. [28]

    Marinelli D, Nuccio A, Di Federico A et al.. “Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2024). PMID: 39389220 ↗

    L1SR_OBSCited in: On the Horizon
  29. [29]

    Han Y, Xiao X, Qin T et al.. “Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis.” Cancer immunology, immunotherapy : CII (2024). PMID: 39382658 ↗

    L1SR_OBSCited in: On the Horizon
  30. [30]

    Zhou N, Leung CH, William WN et al.. “Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer.” Journal for immunotherapy of cancer (2024). PMID: 39448200 ↗

    L2RCTCited in: On the Horizon
  31. [31]

    Ross HJ, Kozono D, Wang XF et al.. “Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 39052256 ↗

    L2RCTCited in: On the Horizon
  32. [32]

    Papaporfyriou A, Bartziokas K, Apessos I et al.. “Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review.” Current oncology (Toronto, Ont.) (2024). PMID: 39451773 ↗

    L5SR_OBSCited in: On the Horizon

Revision History

All updates applied to this page

Loading revisions…